# SAMSARA BIOCAPITAL, LLC: Form 13F holdings

An institutional investment manager in PALO ALTO, CA. SEC CIK 1744967.

- Quarter ended: 2026-06-30
- Filed: 2026-08-14
- Reported value: $1.22bn
- Positions: 24 (24 lines in the filing's table; lines for the same security and option type are added together here)
- Compared with: the 13F for the quarter ended 2026-03-31
- Filing: https://www.sec.gov/Archives/edgar/data/1744967/000174496726000010/

## Holdings

As filed, largest first. Reported value is what the manager stated at the quarter end (Jun 30, 2026), in US dollars; it is filing data, not a price. Weight is the share of the total reported value.

| Issuer | Class | Reported value | Weight | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | ---: | --- | --- |
| [SCHOLAR ROCK HLDG CORP (SRRK)](/companies/srrk.md) | COM | $379.4m | 31.2% | 6,897,652 |  | Unchanged |
| [ALUMIS INC (ALMS)](/companies/alms.md) | COM | $178.6m | 14.7% | 6,345,219 |  | Unchanged |
| [MINERALYS THERAPEUTICS INC (MLYS)](/companies/mlys.md) | COM | $158.4m | 13.0% | 5,871,018 |  | Unchanged |
| [SEPTERNA INC (SEPN)](/companies/sepn.md) | COM | $105.5m | 8.7% | 3,149,128 |  | Unchanged |
| [ALAMAR BIOSCIENCES INC (ALMR)](/companies/almr.md) | COMMON STOCK | $67.2m | 5.5% | 2,480,310 |  | New +2,480,310 |
| [NEUROGENE INC (NGNE)](/companies/ngne.md) | COM | $54.0m | 4.4% | 1,717,127 |  | Unchanged |
| [KALARIS THERAPEUTICS INC (KLRS)](/companies/klrs.md) | COM | $52.4m | 4.3% | 12,881,175 |  | Reduced −66,906 |
| [SPYGLASS PHARMA INC (SGP)](/companies/sgp.md) | COM SHS | $47.0m | 3.9% | 2,109,953 |  | Unchanged |
| [SUTRO BIOPHARMA INC (STRO)](/companies/stro.md) | COM SHS | $35.3m | 2.9% | 1,062,872 |  | Unchanged |
| [INVENTIVA SA (IVA)](/companies/iva.md) | ADS | $23.9m | 2.0% | 6,314,805 |  | Added +1,120,000 |
| [JADE BIOSCIENCES INC (JBIO)](/companies/jbio.md) | COM NEW | $16.4m | 1.3% | 736,237 |  | Reduced −232,561 |
| [PARABILIS MEDICINES INC (PBLS)](/companies/pbls.md) | COM | $15.2m | 1.3% | 556,044 |  | New +556,044 |
| [VTV THERAPEUTICS INC (VTVT)](/companies/vtvt.md) | CL A NEW | $11.2m | 0.9% | 298,496 |  | Unchanged |
| [AQUESTIVE THERAPEUTICS INC (AQST)](/companies/aqst.md) | COM | $10.4m | 0.9% | 2,500,000 |  | Unchanged |
| [NKARTA INC (NKTX)](/companies/nktx.md) | COM | $9.9m | 0.8% | 3,507,666 |  | Unchanged |
| [ARTIVA BIOTHERAPEUTICS INC (ARTV)](/companies/artv.md) | COM | $9.3m | 0.8% | 954,861 |  | New +954,861 |
| [RANI THERAPEUTICS HLDGS INC (RANI)](/companies/rani.md) | COM CL A | $7.9m | 0.6% | 10,369,159 |  | Added +1,869,159 |
| [AGOMAB THERAPEUTICS NV (AGMB)](/companies/agmb.md) | SPONSORED ADS | $7.8m | 0.6% | 600,000 |  | Unchanged |
| [ABIVAX SA (ABVX)](/companies/abvx.md) | SPONSORED ADS | $7.3m | 0.6% | 55,095 |  | Reduced −1,486 |
| [X4 PHARMACEUTICALS INC (XFOR)](/companies/xfor.md) | COM NEW | $6.5m | 0.5% | 1,395,587 |  | Reduced −436,979 |
| [ELOXX PHARMACEUTICALS INC (ELOX)](/companies/elox.md) | COM NEW | $5.6m | 0.5% | 400,000 |  | New +400,000 |
| [COHERUS ONCOLOGY INC (CHRS)](/companies/chrs.md) | COM | $4.8m | 0.4% | 3,428,571 |  | Unchanged |
| [UPSTREAM BIO INC (UPB)](/companies/upb.md) | COM | $2.4m | 0.2% | 353,717 |  | Reduced −382,330 |
| GOSSAMER BIO INC | COM | $1.2m | <0.1% | 7,222,559 |  | Unchanged |

## Sold out

Held at the end of the quarter before and not reported this quarter.

| Issuer | Class | Reported value | Weight | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | ---: | --- | --- |
| ARCELLX INC | COMMON STOCK | $0 | 0.0% | 0 |  | Sold out −60,873 |
| [PALVELLA THERAPEUTICS INC NE (PVLA)](/companies/pvla.md) | COM | $0 | 0.0% | 0 |  | Sold out −38,432 |

Source: SEC EDGAR, Form 13F-HR, accession 0001744967-26-000010. Last ingested by Listed: Oct 22, 2026, 05:26 ET. No prices; not investment advice.